Hemophilia A is an inherited, X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). The disease, which has an incidence of 1 in 6000 male births, can be defined as mild, moderate, or severe depending on the level of FVIII deficiency. The therapy relies upon the occasional administration of the deficient factor in the case of bleeding ("on demand" treatment), or regular factor VIII administration in order to prevent bleedings (“prophylaxis”). It seems likely that primary prophylaxis, initially more expensive, after some years improves the Quality of Life of patients; in the long distance primary prophylaxis might result a cost-effective strategy due to a significant reduction of hemophilia-related comorbidities. Therefore, primary prophylaxis in Hemophiliacs might exert even a reduction of the economic impact on regional health costs.

Coagulation Factor VIII: pharmacoeconomic evaluation and quality of life as measuring tools in clinical practice

MILLA, Paola;CATTEL, Luigi
2012

Abstract

Hemophilia A is an inherited, X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). The disease, which has an incidence of 1 in 6000 male births, can be defined as mild, moderate, or severe depending on the level of FVIII deficiency. The therapy relies upon the occasional administration of the deficient factor in the case of bleeding ("on demand" treatment), or regular factor VIII administration in order to prevent bleedings (“prophylaxis”). It seems likely that primary prophylaxis, initially more expensive, after some years improves the Quality of Life of patients; in the long distance primary prophylaxis might result a cost-effective strategy due to a significant reduction of hemophilia-related comorbidities. Therefore, primary prophylaxis in Hemophiliacs might exert even a reduction of the economic impact on regional health costs.
RATIONALIZATION FOR HIGH-COST DRUGS
Torino, Italia
5 ottobre 2012
RATIONALIZATION FOR HIGH-COST DRUGS
Azygos srl
8
8
Pharmacoeconomics; Hemophilia A
F. Donato; M. Ferroni; M. Messina; P. Schinco; M. Marengo; A. Elia; F. Cattel; P. Milla; M. Miglietta; L. Cattel
File in questo prodotto:
File Dimensione Formato  
Pagina 8 da abstract_spesa_farmaci.pdf

Accesso aperto

Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 97.64 kB
Formato Adobe PDF
97.64 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/121429
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact